(-)-[3R,4S]-Chromanol 293B

(HB1076)

Certificate of Analysis

Latest Certificate of Analysis

Download the latest CoA for this product:

Download CoA

Download Batch-Specific CoA

To download the CoA for a batch, enter the batch ID below:

Technical documents: CoA SDS Datasheet

Product overview

Name (-)-[3R,4S]-Chromanol 293B
Purity >98%
Description Selective delayed rectifier K+ current inhibitor
Write Your Own Review
You're reviewing:(-)-[3R,4S]-Chromanol 293B
Rate this item:

Biological Data

Biological description Selective delayed rectifier K+ current (IKs) inhibitor (IC50 = 1.36 µM). Enantiomer of Chromanol 293B; more potent than the (+)-(3S,4R) enantiomer (IC50 = 9.6 µM). Shows an open channel time-dependent block.

Solubility & Handling

Storage instructions Room temperature
Solubility overview Soluble in ethanol (100mM, gentle warming) or DMSO (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name N-[(3R,4S)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methylethanesulfonamide
Molecular Weight 324.39
Chemical structure (-)-[3R,4S]-Chromanol 293B  [163163-24-4] Chemical Structure
Molecular Formula C15H20N2O4S
CAS Number 163163-24-4
PubChem identifier 121846
SMILES CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)OC2=C1C=C(C=C2)C#N
InChi InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3/t13-,14+/m0/s1
InChiKey HVSJHHXUORMCGK-UONOGXRCSA-N

References for (-)-[3R,4S]-Chromanol 293B

References are publications that support the biological activity of the product
  • A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B.

    Seebohm G et al (2001) Br J Pharmacol 134(8) : 1647-54.
  • Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.

    Yang IC et al (2000) J Pharmacol Exp Ther 294(3) : 955-62.
  • Molecular impact of MinK on the enantiospecific block of I(Ks) by chromanols.

    Lerche C et al (2000) Br J Pharmacol 131(8) : 1503-6.

3 Item(s)